 - Patient must have histologically confirmed, advanced FIGO Stage III or IV high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have completed first line platinum based chemotherapy neoadjuvant or adjuvant 